THE SERIES The 10 volumes in this series record a fifty year history of neuropsychopharmacology related by 213 pioneer clinical, academic, industrial and basic scientists in videotaped interviews, conducted by 66 colleagues between 1994 and 2008. These volumes include a preface by the series editor placing its contents in an historical context and linking each volume to the next. Each volume is dedicated to a former President of the ACNP and edited by a distinguished historian or Fellow of the College who provides an ...
Read More
THE SERIES The 10 volumes in this series record a fifty year history of neuropsychopharmacology related by 213 pioneer clinical, academic, industrial and basic scientists in videotaped interviews, conducted by 66 colleagues between 1994 and 2008. These volumes include a preface by the series editor placing its contents in an historical context and linking each volume to the next. Each volume is dedicated to a former President of the ACNP and edited by a distinguished historian or Fellow of the College who provides an introduction to its themes and a biography of each scientist's career. The series provides insights into a half century of discovery and innovation with its rewards and disappointments, progress and setbacks, including future expectations and hopes for the field as a whole and the ACNP as an organization. IN THIS VOLUME In the first two volumes of this series interviewees reflect on their contributions to the delineation of the effect of psychotropic drugs on behavioral measures (Volume 1: Starting Up) and on neurophysiological parameters (Volume 2: Neurophysiology). In Volume 3, the emphasis shifts as interviewees reflect on their contributions to neuropharmacological research which has been the moving force in psychotropic drug development during the last fifty years. Dedicated to Bernard B. Brodie, this volume is edited by Fridolin Sulser, one of the leaders in the field during "The Neurotransmitter Era" who has made major contributions to studying the mode of action of antidepressants.
Read Less
